Company profile
Medexus Pharmaceuticals Inc.
OTC: MEDXF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Bolton, ONReports USD
#353 of 1,418 Healthcare companies by revenue33rd-percentile growth
EA Score
64CFH 71DQ —GM 48SS 56
v0.1 · 45/100 weight · provisional
↑ operating margin, return on assets · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$102.6M
Rev growth YoY (TTM)
-2.9%
Net income (FY)
-$2.4M
Employees
90
as of 2026-08-18
Market cap
$116.8M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$99.3M$99.3M2026
Net income-$2.4M-$2.4M2026
Operating income$5.8M$5.8M2026
Total assets$147.3M$147.3M2026
Liabilities$98.3M$98.3M2026
Equity$49.0M$49.0M2026
Revenue trend
FY2019 – FY2026 · USD
FY19
FY20
FY21
FY22
FY23
FY24
FY25
FY26
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Medexus Pharmaceuticals Inc.’s revenue?
Medexus Pharmaceuticals Inc. booked $99.3M in FY2026 revenue, contracting 8.3% year over year — slower than 67% of Healthcare companies we track, at a -2.4% net margin.
Peers · Healthcare
StateHouse Holdings Inc.——Beta Bionics, Inc.58CNeuroPace, Inc.53DButterfly Network, Inc.62CBioLife Solutions, Inc.74BSIGA Technologies, Inc.73BKey facts
CEOKenneth d'Entremont
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersBolton, ON
ExchangeOTC: MEDXF
Employees90
IPO date2017-11-27
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.